Clinical Rheumatology

, Volume 24, Issue 2, pp 99–102 | Cite as

Clinical and laboratory features of scleroderma patients developing skeletal myopathy

  • Yoshihiro Mimura
  • Hironobu Ihn
  • Masatoshi Jinnin
  • Yoshihide Asano
  • Kenichi Yamane
  • Kunihiko Tamaki
Original Article


Skeletal muscle involvement, or myopathy, has been a recognized feature of systemic sclerosis (SSc). We studied retrospectively 302 Japanese patients with SSc to elucidate the clinical and laboratory features in scleroderma patients developing skeletal myopathy during their clinical course. Forty-three patients (14%) developed skeletal myopathy during their course of the disease. The mean age of the patients who developed skeletal myopathy was significantly lower than that of those who did not. The ratio of male to female was significantly higher in the myopathic patients. The patients with diffuse cutaneous SSc were more likely to develop myopathy than those with limited cutaneous SSc. The prevalences of heart involvement, pulmonary fibrosis, diffuse pigmentation of the skin, and contracture of phalanges were significantly greater in those with skeletal myopathy than in those without. None of the patients with skeletal myopathy had anticentromere antibody. These findings suggested that the SSc patients with severe internal organ involvement, such as pulmonary fibrosis and heart disease, and some other complications were prone to develop skeletal myopathy during their clinical course of the disease.


Skeletal muscle involvement Systemic sclerosis 


  1. 1.
    Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130–140PubMedGoogle Scholar
  2. 2.
    Westphal CFO (1876) Zwei Fälle von Schlerodermie. Charité Ann (Berlin) 3:341–360Google Scholar
  3. 3.
    Medsger TA, Rodnan GP, Moosy J, et al. (1968) Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 11:554–568PubMedGoogle Scholar
  4. 4.
    Thompson JM, Bluestone R, Bywaters EGL, et al. (1969) Skeletal muscle involvement in systemic sclerosis. Ann Rheum Dis 28:281–288Google Scholar
  5. 5.
    Clements PJ, Frust DE, Campion DS, et al. (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 21:62–71PubMedGoogle Scholar
  6. 6.
    Follansbee W, Zerbe T, Medsger T (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association. Am Heart J 125:194–203CrossRefPubMedGoogle Scholar
  7. 7.
    Vilppula A (1973) Muscular disorders in some collagen diseases: a clinical electromyographic and biopsy study. Acta Med Scand 540 [Suppl]:5–45Google Scholar
  8. 8.
    Medsger TA (1979) Progressive systemic sclerosis: skeletal muscle involvement. Clin Rheum Dis 5:103–113Google Scholar
  9. 9.
    Hausmanowa-Petrusewicz I, Jablanska S, Blaszczyk M, et al. (1982) Electromyographic findings in various forms of progressive systemic sclerosis. Arthritis Rheum 25:61–65PubMedGoogle Scholar
  10. 10.
    West SG, Killan PJ, Lawless OJ (1981) Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis Rheum 24:662–667PubMedGoogle Scholar
  11. 11.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590PubMedGoogle Scholar
  12. 12.
    Le Roy EC, Black CM, Fleischmajer R, Jablonska S, Kreig T, Medsger TA Jr, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–206PubMedGoogle Scholar
  13. 13.
    Ihn H, Sato S, Fujimoto M, Kikuchi K, Igarashi A, Soma Y, Tamaki K, Takehara K (1996) Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis. Clin Exp Immunol 105:475–479CrossRefPubMedGoogle Scholar
  14. 14.
    Ihn H, Sato S, Tamaki T, et al. (1992) Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 284:391–395PubMedGoogle Scholar
  15. 15.
    Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2004

Authors and Affiliations

  • Yoshihiro Mimura
    • 1
  • Hironobu Ihn
    • 1
  • Masatoshi Jinnin
    • 1
  • Yoshihide Asano
    • 1
  • Kenichi Yamane
    • 1
  • Kunihiko Tamaki
    • 1
  1. 1.Department of Dermatology, Faculty of MedicineUniversity of TokyoBunkyo-ku, TokyoJapan

Personalised recommendations